Drug intelligence / Profile preview

mesenchymal stem cells + secretome

Development stage
Preclinical
Lead developer
Kala Bio
Modality
Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Intraarticular, Intrathecal, Intramuscular, Ophthalmic, Intravitreal, Subretinal, Intracavernosal, Topical, Intraspinal
01

Overview

Mesenchymal stem cells + secretome refers to a combination therapy that utilizes both mesenchymal stem cells (MSCs) and the collection of bioactive factors they secrete, known as the "secretome." MSCs are multipotent adult stem cells capable of differentiating into various cell types and are widely used in regenerative medicine. The MSC secretome is composed of soluble proteins (such as growth factors and cytokines), lipids, free nucleic acids, microvesicles, and exosomes. This combination therapy leverages both the direct regenerative potential of MSCs and the paracrine effects mediated by their secreted products. The mechanism of action involves: - Direct tissue regeneration via differentiation by MSCs. - Paracrine signaling from the secretome that modulates immune responses, reduces inflammation, promotes angiogenesis (formation of new blood vessels), inhibits apoptosis (cell death), supports autophagy modulation, and enhances tissue repair[1][2][4][7]. Therapeutically, this approach aims to overcome limitations associated with cell-based therapies alone—such as low engraftment rates or immunogenicity—by also harnessing potent bioactive molecules in the conditioned media or isolated vesicular fractions[1][2][3]. The combined use is being explored for a wide range of indications including chronic inflammatory diseases, neurological disorders (e.g., multiple sclerosis, ALS), cardiovascular diseases, osteoarthritis/arthritis conditions, spinal cord injuries, erectile dysfunction/impotence recovery after injury or surgery[3], retinal degenerative diseases[5], wound healing[8], among others.

Other names
MSC secretomeMSC-derived secretomemesenchymal stromal cell secretome
02

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)TGFBR2 (TGF-β receptor type 2)IL10RA (Interleukin-10 Receptor)

Beyond the preview

Go deeper on mesenchymal stem cells + secretome.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesenchymal stem cells + secretome.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call